Current signed customers expected to generate $1m annualized reported revenues from precipio's hemescreen pol offering by q4-2021

Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021
PRPO Ratings Summary
PRPO Quant Ranking